PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This program is not certified for continuing education credit. The content provided and opinions expressed are those of the sponsor and/or presenter(s) and are not necessarily those of the AAAAI.

PROGRAM OVERVIEW

Chronic inflammatory airway diseases, including asthma, allergic rhinitis (AR), chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD), remain inadequately controlled in many patients despite guideline-directed therapy, contributing to significant clinical and economic burden. Growing evidence highlights the role of shared epithelial-driven inflammation, linking upper and lower airway diseases through common immune mechanisms. Central to this process are upstream cytokines known as “alarmins,” which initiate and amplify type 2 inflammation. This non-CME program will feature expert, case-based discussions on shared airway inflammation and the evolving role of emerging anti-alarmin therapies in improving outcomes across multiple airway diseases.

Shared Pathways, Shared Solutions: Advancing Anti-Alarmin Care in Asthma, CRSwNP, AR, and COPD